Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Rated “Hold” by Wall Street Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has earned an average rating of “Hold” from the thirteen analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $21.85.

A number of equities analysts have commented on the company. JPMorgan Chase & Co. lowered Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research note on Tuesday, October 20th. Jefferies Financial Group lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 target price on the stock. in a report on Monday, October 19th. HC Wainwright restated a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, October 20th. Stifel Nicolaus initiated coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Citigroup cut their price objective on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research report on Tuesday, August 18th.

Institutional Trading of Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Eyepoint Pharmaceuticals during the third quarter valued at approximately $390,000. Cyndeo Wealth Partners LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 46.8% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 35,519 shares of the company’s stock valued at $116,000 after purchasing an additional 11,329 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at $161,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Eyepoint Pharmaceuticals in the 2nd quarter valued at $72,000. Finally, Squarepoint Ops LLC increased its stake in shares of Eyepoint Pharmaceuticals by 22.3% in the 2nd quarter. Squarepoint Ops LLC now owns 98,002 shares of the company’s stock valued at $1,401,000 after purchasing an additional 17,883 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Up 3.9%

Shares of Eyepoint Pharmaceuticals stock opened at $0.38 on Friday. The stock has a market capitalization of $32.54 million, a price-to-earnings ratio of -0.10 and a beta of 1.67. Eyepoint Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $19.11. The company has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $11.16.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. On average, sell-side analysts anticipate that Eyepoint Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.